New framework aims to modernize atherosclerosis research

A new review in Atherosclerosis argues that atherosclerosis research needs a more integrated playbook, combining large-scale human datasets with newer experimental systems such as multi-omics, polygenic risk scores, artificial intelligence, organ-on-a-chip platforms, and carefully chosen in vivo models. The paper, by Kaloyan Takov, Marie A. C. Depuydt, and Christophe A. T. Stevens, frames residual atherosclerotic cardiovascular disease risk as a signal that current discovery approaches still miss important biology, especially the disease’s heterogeneity across patients and tissues. The authors’ central message is not that one model should replace another, but that discovery science and clinical science need to be linked more deliberately through complementary model systems. (sciencedirect.com)

Why it matters: For veterinary professionals, this is a useful reminder that translational cardiovascular research is moving toward model selection based on the biological question, rather than defaulting to a single animal model or a single dataset. That matters in comparative medicine, where veterinarians contribute to animal model design, welfare oversight, pathology interpretation, and increasingly to cross-species translational work. The broader field is already emphasizing tools such as vasculature-on-a-chip systems for studying atherothrombosis, while recent cardiovascular literature also highlights growing interest in combining clinical, metabolomic, and polygenic risk information for more precise risk prediction. Together, those shifts suggest future preclinical programs may ask more of veterinary teams in study design, biomarker strategy, and model validation. (nature.com)

What to watch: Expect more work aimed at standardizing how human-relevant chip models, multi-omics pipelines, and animal studies are combined, rather than treating them as competing approaches. (sciencedirect.com)